Navigation Links
Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta
Date:8/5/2008

ns except for the four endocrine hormones licensed to Schering-Plough.

ABOUT MODIGENE

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit http://www.modigeneinc.com.

Safe Harbor Statement: This press release contains forward-looking statements, including statements regarding the results of current studies and preclinical experiments and the effectiveness of Modigene's long-acting protein programs and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Modigene's business and prospects, including the risks that Modigene may not succeed in developing any commercial products based upon its long-acting protein technology, including any long-acting versions of human growth hormone, erythropoietin, interferon beta or GLP-1; that the long-acting products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; that the actual dollar amount of any grants from the OCS is uncertain and is subject to policy changes of the Israeli government, and that such grants may be insufficient to assist with product development; and other risks and uncertaint
'/>"/>

SOURCE Modigene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Modigene Platform Validated in Independent Phase III Trial of CTP Technology
2. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
3. GeneGo is Awarded NCI Grant for Development of Systems Biology Platform for Integrative Data Analysis in Cancer
4. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
5. Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S.
6. TriLink Awarded a Phase II Grant for a Second Hot Start PCR Project
7. New Patent Awarded for Antigen-Sparing Vaccines that Elicit Robust Immunity
8. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
9. DiObex, Inc. Awarded Patent for the Prevention of Insulin-Induced Hypoglycemia
10. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
11. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... , Nov. 22, 2014  Sprout Pharmaceuticals today announced ... demonstrate that women treated with flibanserin up to 200 mg ... data were presented at the 20 th Annual Fall ... North America in Miami . ... response to the Complete Response Letter and the Formal Dispute ...
(Date:11/22/2014)... , Nov. 22, 2014  New data demonstrates ... the most common form of female sexual dysfunction, Hypoactive ... function or driving performance in premenopausal women when taken ... Medicine Society of North America,s ... Miami . SMSNA accepted this ...
(Date:11/22/2014)... Nov. 21, 2014  CytoSorbents Corporation (OTCQB: CTSO), ... Union approved CytoSorb® cytokine adsorber to treat critically-ill ... Beacon of Light Award at last night,s New ... Dr. Phillip Chan , Chief Executive ... to be recognized by the New Jersey Tech ...
Breaking Medicine Technology:Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 2Study on Efficacy and Sedation-Related Safety of Flibanserin in Premenopausal Women Released Today at Sexual Medicine Society of North America Meeting 3CytoSorbents Wins Beacon of Light Award 2CytoSorbents Wins Beacon of Light Award 3CytoSorbents Wins Beacon of Light Award 4
... 16 , - Promising Efficacy ... Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) ... II studies evaluating,the efficacy, safety and tolerability of QVA149 at ... QVA149 is a novel once-daily,dry powder fixed dose bronchodilator combination ...
... , , ... Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ) today ... rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from ... 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) ...
Cached Medicine Technology:QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 2QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 3QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) 6
(Date:11/23/2014)... To show thanks to new and old customers, ... white evening dresses for weddings. Customers who need custom ... is a distinguished dress manufacturer, and it is among the ... for a very long time. The CEO of this company ... be able to buy not only a beautiful dress, but ...
(Date:11/23/2014)... SWAccessControl.com's high quality access control power suppliers ... has announced its new collection of power suppliers. Additionally, ... quality power suppliers. All the new models come with ... lasts until Dec. 20, 2014. , SWAccessControl.com has thousands ... supporting it for a long time. It is very ...
(Date:11/23/2014)... More than two dozen new claims were ... involving Byetta lawsuits ( http://www.byettalawsuit2013.com/ ), as well as ... , A Case List updated on November 17th ... 2 diabetes medications referred to as incretin mimetics have ... District of California, where a federal proceeding continues to ...
(Date:11/23/2014)... AngelWeddingDress.com has recently updated ... of beach wedding dresses. “If you are looking for ... as soon as possible. Here you can enjoy 70% ... says. , Holding a big marriage ceremony is the ... beautiful beach wedding dress is uppermost priority. Ophelia, one ...
(Date:11/23/2014)... CA (PRWEB) November 23, 2014 ... American Medical Aesthetics & Wellness was recently featured ... Milgrom, Ph.D. is president and CEO of American Medical ... Dr. Asher Milgrom received a full scholarship to attend ... the Medical School at the University of Chicago, where ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4Health News:Beach Wedding Dresses Added to Outstanding Online Dress Company AngelWeddingDress.com 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 2Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 3Health News:Asher Milgrom Is the Founding Doctor of AMA Skincare and Is Featured in the International Business Times 4
... Development, and Health at Harvard School of Public Health, has ... found that the disease costs a person $3.2 million over ... the new book Understanding Autism: From Basic Neuroscience to Treatment ... Autism,” Ganz says that autism costs $35 billion per year ...
... open a second cancer hospital, this time in the southern ... up in Karachi by January next year, the Daily Times ... had set up the Shaukat Khanum Memorial Cancer Hospital and ... state-of-the-art cancer centre was Khan's tribute to his mother Shaukat ...
... of the Irish Medical Organization (IMO) has expressed his interest ... . Previously, Nora Owen, the party’s former Justice Minister held ... nomination in the Dublin North constituency and is positive about ... held on the 2nd of May. ,‘The people ...
... flu in ducks on Indonesia's resort island of Bali, health ... of bird flu// . The birds had been smuggled to ... Putra, senior government veterinarian. ,More than 24 bird ... most populous nation. In response to the above situation, import ...
... Researchers from the Simon Bolivar University in Caracas found ... the beans reduced its flatulence capacity// and increased the ... of nutrition especially in the developing countries. ... method of creating flatulence-free beans but not compromising on ...
... University suggests that men are more aware of potential rivals ... The researchers felt that men// become more jealous and wary ... their most fertile. ,The Evolution and Human Behaviour ... with ovulating partners were vary wary of the dominant looking ...
Cached Medicine News:Health News:The Price Of Autism 2Health News:Jealousy In Men Peaks When Partners Are Most Fertile 2
... Millbrook Practice Manager® is now known ... (PM). Centricity Physician Office - PM is ... and structure, providing an easily adaptable solution ... physician offices of every specialty and ...
... practice management systems have brought cutting-edge software ... in the world. Today, Intuition PM delivers ... a friendly, intuitive manner. Automate patient registration ... in-office patient processing through wireless hand-held PC's, ...
... Electronic Medical Records module is designed ... costs and increase revenues. It creates ... minimal effort while it streamlines workflow, ... related to patient care outcomes. NextGen ...
... Intuition EMR family of products offers ... range of specialties. Intuition EMR enables ... full electronic record at the point ... spend less time on documentation and ...
Medicine Products: